UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

Leukemia, 2009-12, Vol.23 (12), p.2210-2221

2009

Volltextzugriff (PDF)

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

Leukemia, 2014-02, Vol.28 (8), p.1725-1735

2014

Volltextzugriff (PDF)

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

Leukemia, 2014-08, Vol.28 (8), p.1725-1735

2014

Volltextzugriff (PDF)

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

Leukemia, 2011-06, Vol.25 (6), p.1026-1035

2011

Volltextzugriff (PDF)

Advances in the pathogenesis and diagnosis of multiple myeloma

International journal of laboratory hematology, 2015-05, Vol.37 (S1), p.108-114

2015

Volltextzugriff (PDF)

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

Leukemia, 2013-12, Vol.27 (12), p.2357-2365

2013

Volltextzugriff (PDF)

Targeting vasculogenesis to prevent progression in multiple myeloma

Leukemia, 2016-05, Vol.30 (5), p.1103-1115

2016

Volltextzugriff (PDF)

Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma

Leukemia, 2017-04, Vol.31 (4), p.967-970

2017

Volltextzugriff (PDF)

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Blood cancer journal (New York), 2017-03, Vol.7 (3), p.e549-e549

2017

Volltextzugriff (PDF)

Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VKMYC model of multiple myeloma

Haematologica (Roma), 2015-06, Vol.100 (6), p.834-841

2015

Volltextzugriff (PDF)

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations

Leukemia, 2006-05, Vol.20 (5), p.807-813

2006

Volltextzugriff (PDF)

The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma

Oncogene, 2014-01, Vol.33 (3), p.316-325

2014

Volltextzugriff (PDF)

The VkMYC Mouse Model to study Drug and Immunotherapy Response and Resistance

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e3-e4

2015

Volltextzugriff (PDF)

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic VkMYC multiple myeloma

Cell death & disease, 2013-09, Vol.4 (9), p.e798-e798

2013

Volltextzugriff (PDF)

P881: CDK7 CONTRIBUTES TO METABOLIC REPROGRAMMING IN MM CELLS THROUGH C‐MYC MEDIATED TRANSCRIPTIONAL CONTROL OF GLYCOLYTIC GENES

HemaSphere, 2022-06, Vol.6 (Suppl), p.773-774

2022

Volltextzugriff (PDF)

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

Nature genetics, 1997-07, Vol.16 (3), p.260-264

1997

Volltextzugriff (PDF)

555 CB-5083, a first in class inhibitor of the AAA-ATPase p97/VCP, induces irresolvable ER stress that results in antitumor activity in solid and hematological tumor models

European journal of cancer (1990), 2014-11, Vol.50, p.180-180

2014

Volltextzugriff (PDF)

MYC dysregulation in the progression of multiple myeloma

Leukemia, 2020-01, Vol.34 (1), p.322-326

2020

Volltextzugriff (PDF)

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

Cancer cell, 2008-02, Vol.13 (2), p.167-180

2008

Volltextzugriff (PDF)

The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells

Blood, 2001-04, Vol.97 (8), p.2413-2419

2001

Volltextzugriff (PDF)

Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution

Leukemia, 2007-11, Vol.21 (11), p.2358-2359

2007

Volltextzugriff (PDF)

Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma

Annals of oncology, 2000, Vol.11 (suppl-1), p.S131-S135

2000

Volltextzugriff (PDF)

Ploidy status rarely changes in myeloma patients at disease progression

Leukemia research, 2006-03, Vol.30 (3), p.266-271

2006

Volltextzugriff (PDF)

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma

Blood, 2004-05, Vol.103 (9), p.3521-3528

2004

Volltextzugriff (PDF)

1 – 25 von 362

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(301)
Mit Volltextzugriff
(332)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(234)
Life Sciences & Biomedicine
(121)
Humans
(117)
Physics
(97)
Physical Sciences
(90)
Technology
(90)
Nuclear Science & Technology
(66)
Physics, Nuclear
(59)
Physics, Particles & Fields
(59)
Instruments & Instrumentation
(51)
Female
(48)
Male
(46)
Animals
(45)
Hematology
(38)
Multiple Myeloma - Genetics
(38)
Mice
(33)
Engineering
(32)
Detectors
(31)
Detectors And Experimental Techniques
(28)
Child
(27)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

Advances in the pathogenesis and diagnosis of multiple myeloma

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

Targeting vasculogenesis to prevent progression in multiple myeloma

Induction of iron excess restricts malignant plasma cells expansion and potentiates bortezomib effect in models of multiple myeloma

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control

Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VKMYC model of multiple myeloma

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations

The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma

The VkMYC Mouse Model to study Drug and Immunotherapy Response and Resistance

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic VkMYC multiple myeloma

P881: CDK7 CONTRIBUTES TO METABOLIC REPROGRAMMING IN MM CELLS THROUGH C‐MYC MEDIATED TRANSCRIPTIONAL CONTROL OF GLYCOLYTIC GENES

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

555 CB-5083, a first in class inhibitor of the AAA-ATPase p97/VCP, induces irresolvable ER stress that results in antitumor activity in solid and hematological tumor models

MYC dysregulation in the progression of multiple myeloma

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution

Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma

Ploidy status rarely changes in myeloma patients at disease progression

Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma

Suchergebnisse filtern